Organic Active Ingredients TRIZ Cases

Acyclic CB[n] molecular containers resolve poor drug bioavailability by forming non-covalent complexes that boost solubility up to 2750-fold.

An isoindolin-1-one derivative acts as an allosteric inhibitor to target activated and resistant forms of the EGFR protein.

Combining RAF and MEK inhibitors targets solid tumors with RAS Q61 or G13R mutations, resolving limited treatment effectiveness in NRAS-mutant melanoma.

Heteroaryl substituted aminopyridine compounds inhibit IRAK-4 to treat inflammatory diseases.

Specific heterocyclic substitutions on the pyridine ring enable selective antifungal activity while minimizing mammalian host toxicity.

Quinolone derivatives form irreversible covalent bonds with fibroblast growth factor receptors to inhibit their activity.

Vitamin D glycoside prodrugs activate via tissue enzymes to release active vitamin D locally, preventing systemic hypercalcemia.

Oxetane-substituted compounds enhance aqueous solubility of poorly soluble radioprotectors, resolving precipitation issues while accelerating bone healing.

Substituted bicyclic aza-heterocycles modulate sirtuin proteins to treat aging-related diseases while reducing the side effects of existing therapies.

A bromo-nitrile cyclization process prepares (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine intermediates.

Segmented molecular design achieves selective ROMK inhibition to treat hypertension while avoiding hypokalemia side effects.

Quinazoline derivatives inhibit DNA methyltransferase to restore tumor suppressor gene expression while improving bioavailability over nucleoside analogues.

Nitrogenous aromatic heterocyclic compounds inhibit ALK5 via palladium-catalyzed coupling reactions.

Orotic acid lowers core body temperature by activating the hepatic urea cycle to reduce metabolic heat production without external instruments.

Merges AKT and WEE1 inhibitors to overcome single-agent resistance in metastatic melanoma while managing side effects through selective pathway targeting.

Cleavable phosphonomethoxy prodrugs enhance brain penetration of gamma-secretase modulators to reduce amyloid beta 42 levels.

SYK agonists bypass defective TREM2 receptors to clear amyloid beta plaques and reverse neuronal damage.

Transforming bimatoprost into a stable crystalline form eliminates precipitation risks, maintaining consistent drug potency for glaucoma treatment.

Thermokinetic compounding creates an amorphous deferasirox dispersion that resolves erratic oral absorption and inconsistent bioavailability.

Combining succulent extracts with alginic acid creates a stable shear-thinning system.

Beta-adrenergic inverse agonists block receptor-mediated mucus hypersecretion, resolving the physiological barrier that causes smoking cessation failure.

Formula I pyrrolidine derivatives serve as mGluR5 antagonists, addressing the lack of specific treatments for chronic pain and memory deficits.

Amine addition salts with amino nicotinic acid derivatives resolve the trade-off between water solubility and hygroscopic instability in DHODH inhibitors.

Converting the compound to a deanol salt resolves contradictions between therapeutic activity and physical stability, ensuring better bioavailability.

Acid hydrolyzed Picrorhiza kurroa extract increases skin thickness and hydration, reducing senile purpuras without irritation.

Novel heterocyclic CGRP receptor antagonists utilize non-oral delivery routes to treat migraine disorders.

Replacing hazardous trimethylaluminum with safer catalysts improves reaction yield while eliminating safety hazards from violent water reactions.

ROR2 inhibitors target the ROR2 pathway to enhance cartilage repair, addressing osteoarthritis progression by suppressing degrading enzymes.

Segmenting the receptor allows cytosolic tail modulators to bypass ectodomain ligand requirements, resolving poor understanding of activation mechanisms.

Removing the amide carbonyl group from SR142948 derivatives improves tumor uptake and expands the therapeutic window for alpha-emitter radioligand therapy.

Amino-functionalized silica stationary phase separates cannabinoids from impurities, achieving high purity yields without complex multi-stage processing.

Specific deutetrabenazine particle sizing balances dissolution profile against product degradation for bioequivalent tablets.

A coalescing filter directs wet gas against a lower endplate to drain liquid, preventing saturation and extending filter life.

Co-administering an antiestrogen with an androgen or aromatase inhibitor elevates testosterone levels in male mammals.

Cannabigerol compounds mitigate seizures without inducing the hypnotic side effects associated with cannabidiol treatments.

Cyano thienotriazolodiazepine compounds bind bromodomain proteins, inhibiting activity while balancing potency and safety profiles.

Segmentation and intermediary linkers improve target specificity while reducing adverse effects on non-target tissues.

6-(1H-imidazo-1-yl)-2-aryl quinazoline derivatives inhibit monoamine oxidase and bind imidazoline receptors to reduce hypertensive crisis risks.

Extracting (24S)-3β-hydroxy-5α-stigmastan-6-one from plumula nelumbinis identifies the active compound that increases NAD+ content and treats type 2 diabetes.

Ambrosia maritima extracts inhibit viral replication and gene expression by targeting the spike protein, main protease, and RNA-dependent RNA polymerase.

Unnatural amino acids introduce specific functional groups to peptides, resolving the trade-off between biological compatibility and functional diversity.

Magnetic nanoparticles transport therapeutic cargo across the blood-brain barrier using external magnetic forces.

6-Methoxybenzoxazolinone downregulates TGF-β/SMAD signaling to reduce liver fibrosis without severe side effects.

Short-chain fructooligosaccharides stimulate offspring growth through gut microbiota modulation.